Nuevocor
Nuevocor is an IND-stage biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology. Their proprietary PrOSIATM platform aims to address the root cause of disease across multiple cardiomyopathies, specifically focusing on LMNA-related dilated cardiomyopathy (LMNA DCM). The company's lead candidate, NVC-001, is a first-in-class, AAV-based gene therapy currently in Phase 1/2 clinical trials.
Funding Round: Series B
Funding Amount: $45M
Date: 06-May-2025
Investors: Kurma Partners, Angelini Ventures, EDBI, ClavystBio, Boehringer Ingelheim Venture Fund, Highlight Capital, SEEDS Capital
Markets: Biotech, Gene Therapy, Healthcare
HQ: Singapore, Singapore
Founded: 2020
Website: https://www.nuevocor.com/
LinkedIn: https://www.linkedin.com/company/nuevocor
Crunchbase: https://www.crunchbase.com/organization/nuevocor
Leave a Comment
Comments
No comments yet.